Estrogenic and Antiestrogenic Activities of 16alpha- and 2-hydroxy Metabolites of 17beta-estradiol in MCF-7 and T47D Human Breast Cancer Cells
Overview
Molecular Biology
Authors
Affiliations
The comparative mitogenic activities of 17beta-estradiol (E2) and four metabolites, 2-hydroxyestradiol (2-OHE2), 2-hydroxyestrone (2-OHE1), 16alpha-hydroxyestradiol (16alpha-OHE2) and 16alpha-hydroxyestrone (16alpha-OHE1) were determined in estrogen receptor (ER)-positive MCF-7 and T47D human breast cancer cells. E2 (1 nM) induced a 7- to 13-fold increase in cell number in both cell lines compared to untreated cells and the mitogenic potencies of 16alpha-OHE1 or 16alpha-OHE2 were comparable to or greater than E2. In contrast, 2-OHE1 and 2-OHE2 were weak mitogens in both cell lines and in cells cotreated with 1 nM E2 and 100 or 1000 nM 2-OHE1 or 2-OHE2, there was a significant inhibition of hormone-induced cell proliferation. The comparative ER agonist/antagonist activities of E2 and the metabolites on transactivation were determined in T47D cells transiently transfected with constructs containing promoter inserts from the cathepsin D (pCD) and creatine kinase B (pCKB) genes. E2, 16alpha-OHE2 and 16alpha-OHE1 induced reporter gene activity in both MCF-7 or T47D cells transfected with pCKB or pCD. In contrast, 2-OHE1 and 2-OHE2 did not exhibit ER agonist activity for these transactivation assays, but in cells cotreated with E2 plus 2-OHE1 or 2-OHE2, there was a significant decrease in the hormone-induced response. These results demonstrate that 16alpha-OHE1/16alpha-OHE2 exhibit estrogenic activities similar to that observed for E2, whereas the 2-catecholestrogens are weak ER agonists (cell proliferation) or antagonists (cell proliferation and transactivation).
Human Cytochrome P450 Cancer-Related Metabolic Activities and Gene Polymorphisms: A Review.
Mokhosoev I, Astakhov D, Terentiev A, Moldogazieva N Cells. 2024; 13(23).
PMID: 39682707 PMC: 11639897. DOI: 10.3390/cells13231958.
Salvio G, Ciarloni A, Gianfelice C, Lacche F, Sabatelli S, Giacchetti G Antioxidants (Basel). 2023; 12(10).
PMID: 37891909 PMC: 10604028. DOI: 10.3390/antiox12101830.
Natural products as drug candidates for breast cancer (Review).
Telang N Oncol Lett. 2023; 26(2):349.
PMID: 37427344 PMC: 10326826. DOI: 10.3892/ol.2023.13935.
Telang N Int J Mol Sci. 2022; 23(9).
PMID: 35563193 PMC: 9105252. DOI: 10.3390/ijms23094800.
In Silico Prediction of Steroids and Triterpenoids as Potential Regulators of Lipid Metabolism.
Dembitsky V Mar Drugs. 2021; 19(11).
PMID: 34822521 PMC: 8618826. DOI: 10.3390/md19110650.